MedTrace Logo

β-alanine in the Treatment of Advanced Hepatocellular Carcinoma

NCT07317414 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 158

Last updated 2026-01-05

No results posted yet for this study

Summary

This study is a prospective, randomized controlled study on nutritional support and metabolic regulation. It assesses the safety, compliance, and improvement of metabolic/physical-related indicators when using β-alanine within the specified dose range as dietary supplementation, in addition to the standard first-line treatment. The anti-tumor efficacy (ORR, PFS, OS) is the exploratory endpoint.

Conditions

Interventions

DRUG

Atezolizumab combined with bevacizumab combined with β- alanine

Atezolizumab (Tecentriq®) + Bevacizumab (Avastin®)+β- alanine

DRUG

Atezolizumab combined with bevacizumab

Atezolizumab (Tecentriq®) + Bevacizumab (Avastin®)

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-24
Primary Completion
2028-12-05
Completion
2030-12-05

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07317414 on ClinicalTrials.gov